Equities

Molecular Templates Inc

MTEM:NAQ

Molecular Templates Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.35
  • Today's Change-0.01 / -0.74%
  • Shares traded39.51k
  • 1 Year change-80.10%
  • Beta1.1562
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1261143
Total Receivables, Net0.25--0
Total Inventory------
Prepaid expenses2.203.463.92
Other current assets, total2.803.791.25
Total current assets1768148
Property, plant & equipment, net172628
Goodwill, net------
Intangibles, net0.600.701.10
Long term investments--08.99
Note receivable - long term------
Other long term assets1.462.796.14
Total assets3598192
LIABILITIES
Accounts payable1.520.501.61
Accrued expenses6.771112
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total9.034633
Total current liabilities175747
Total long term debt03635
Total debt03635
Deferred income tax------
Minority interest------
Other liabilities, total141945
Total liabilities31113127
SHAREHOLDERS EQUITY
Common stock0.010.060.06
Additional paid-in capital457430418
Retained earnings (accumulated deficit)(453)(445)(352)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.07)(0.05)
Total equity4.21(15)66
Total liabilities & shareholders' equity3598192
Total common shares outstanding5.373.763.75
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.